Risedronate reverses bone loss in postmenopausal women with low bone mass : Results from a multinational, double-blind, placebo-controlled trial

Journal article

Peer reviewed

I Fogelman, C Ribot, R Smith, D Ethgen, E Sod, J.-Y Reginster and BMD-MN Study Grp

The journal of clinical endocrinology and metabolism, Vol.85(5), pp.1895-1900

01/05/2000

PMID: 10843171

Abstract

Biological and medical sciences

Bones, joints and connective tissue. Antiinflammatory agents

Medical sciences

Pharmacology. Drug treatments

1 Record Views

Title: Risedronate reverses bone loss in postmenopausal women with low bone mass : Results from a multinational, double-blind, placebo-controlled trial
Creators - without role: I Fogelman - Guy's Hospital
C Ribot - Department of Endocrinology, Hospital Rangueil, Toulouse 31403, France
R Smith - Oxford Health Management Ltd., Acland Hospital, Oxford S10 2RX, United Kingdom
D Ethgen - Procter & Gamble
E Sod - Procter & Gamble Pharmaceuticals, Mason, Ohio 45040, United States
J.-Y Reginster - Bone/Cartilage Metabolism Unit, Polycliniques L. Brull, 4020 Liege, Belgium
BMD-MN Study Grp
Publication Details: The journal of clinical endocrinology and metabolism, Vol.85(5), pp.1895-1900
Publisher: Endocrine Society
Identifiers: 9953198708331
Academic Unit: King Saud University
Language: English
Resource Type: Journal article